E 0474

Drug Profile

E 0474

Latest Information Update: 01 Jul 2003

Price : $50

At a glance

  • Originator Ebewe
  • Class Benzofurans; Class III antiarrhythmics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Arrhythmias

Most Recent Events

  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
  • 09 Jul 1998 New profile
  • 09 Jul 1998 Preclinical development for Arrhythmias in Austria (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top